An ionotropic but not a metabotropic glutamate agonist potentiates the pharmacological effects of olanzapine in the rat

Behavioural Pharmacology

Volumn 16, Issue 8, 2005, Pages 635-642

  Dall'Olio, Rossella ^a   Rimondini, Roberto ^a   Locchi, Federica ^a   Voltattorni, Manuela ^a   Gandolfi, Ottavio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

2 chloro 5 hydroxyphenylglycine; D cycloserine; Dopamine mediated behaviors; Metabotropic glutamate receptor 5; N methyl D aspartate receptors; Olanzapine; Rat; Serotonin mediated behaviors

Indexed keywords

2 CHLORO 5 HYDROXYPHENYGLYCINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ATYPICAL ANTIPSYCHOTIC AGENT; CYCLOSERINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GLYCINE; IONOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; OLANZAPINE; QUINPIROLE; SEROTONIN 2A AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HEAD MOVEMENT; HYPERACTIVITY; MALE; NONHUMAN; RAT; SEROTONINERGIC SYSTEM;

AMPHETAMINES; ANIMALS; APOMORPHINE; BENZODIAZEPINES; CYCLOSERINE; DOPAMINE AGONISTS; DRUG SYNERGISM; EXCITATORY AMINO ACID AGONISTS; EXPLORATORY BEHAVIOR; GLYCINE; INJECTIONS, INTRAVENTRICULAR; MALE; MOTOR ACTIVITY; PHENYLACETATES; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUTAMATE; RECEPTORS, KAINIC ACID; RECEPTORS, METABOTROPIC GLUTAMATE; SEROTONIN UPTAKE INHIBITORS; STEREOTYPED BEHAVIOR;

EID: 27944469991     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200512000-00006     Document Type: Article

References (52)

1. Alagarsamy S, Marino MJ, Rouse ST, Gereau IVRW, Heinemann SF, Conn PJ (1999). Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nat Neurosci 2:234-240.
2. Arnt J, Skarsfeldt T (1998). Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropharmacology 18:64-101.
3. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ (2000). Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20:7871-7879.
4. Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, Moore NA (1997). In vitro and in vivo biochemistry of olanzapine: a novel atypical antipsychotic drug. J Clin Psychiatry 58:28-36.
5. Carlsson M, Engberg G, Carlsson A (1994). Effects of D-cycloserine and (+)HA-966 on the locomotor stimulation induced by NMDA antagonists and clonidine in monoamine-depleted mice. J Neural Transm Gen Sect 95:223-233.
6. Carlsson M, Hansson LO, Waters N, Carlsson ML (1997). Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 61:75-94.
7. Carlsson M, Hansson LO, Waters N, Carlsson ML (1999). A glutamatergic deficiency model of schizophrenia. Br J Psychiatry 37:2-6.
8. Cascella NG, Macciardi F, Cavallini C, Smeraldi E (1994). D-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-study. J Neural Transm Gen Sect 95:105-111.
9. Contreras PC (1990). D-serine antagonized phencyclidine- and MK801-induced stereotyped behavior and ataxia. Neuropharmacology 29:291-293.
10. 2 dopamine receptor blockers in the rat. Psychopharmacology 110:165-168.
11. Dall'Olio R, Rimondini R, Gandolfi O (1994). The NMDA positive modulator D-cycloserine inhibits dopamine-mediated behaviours in the rat. Neuropharmacology 33:55-59.
12. Dall'Olio R, Gandolfi O, Gaggi R (2000). D-Cycloserine, a positive modulator of NMDA receptors, inhibits serotonergic functions. Behav Pharmacol 11:631-637.
13. Depoortere R, Perrault G, Sanger DJ (1999). Prepulse inhibition of the startle reflex in rats: effects of compounds acting at various sites on the NMDA receptor complex. Behav Pharmacol 10:51-62.
14. 2-like' agonist RU 24213. Psychopharmacology 124:40-49.
15. Devon RS, Anderson S, Teague PW, Muir WJ, Murray V, Pelosi AJ, et al. (2001). The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Mol Psychiatry 6:311-314.
16. 1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36:265-267.
17. Goff DC, Coyle JT (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367-1377.
18. Goff DC, Tsai G, Manoach DS, Coyle JT (1995). Dose-finding trial of D-cycloserine in added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213-1215.
19. Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT (1996). D-Cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry 153:1628-1630.
20. Goff DC, Henderson D, Evins A, Amico E (1999). A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 45:512-514.
21. Hashimoto A, Nishikava T, Oka T, Takahashi K (1991). D-Alanine inhibits methamphetamine-induced hyperactivity in rats. Eur J Pharmacol 202:105-107.
22. Heresco-Levy U, Javitt DC (1998). The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes. Eur Neuropsychopharmacology 8:141-152.
23. Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Horowits A, Kelly D (1996). Double-bind placebo-controlled crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169:610-617.
24. Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Silipo G, Lichenstein M (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56:29-36.
25. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC (2002). Placebo-controlled trial of D-cycloserine added to conventional neuroleptics olanzapine, or risperidone in schizophrenia. Am J Psychiatry 159:480-482.
26. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, et al. (2005). D-Serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57:577-585.
27. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer IP (1994). Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236.
28. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, Rodenhiser-Hill J, Mann JJ, Van Heertum RL, et al. (2000). Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 48:627-640.
29. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B (1980). Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Let 20:379-382.
30. Kinney GG, Burno M, Campbell UC, Hernandez LM, Rodriguez D, Bristow LJ, Conn PJ (2003). Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 306:116-123.
31. Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, et al. (2005). A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 313:199-206.
32. Laruelle M, Kegeles LS, Abi-Dargham A (2003). Glutamate, dopamine and schizophrenia from pathophysiology to treatment. Ann NY Acad Sci 1003:138-158.
33. Mannaioni G, Marino MJ, Valenti O, Traynelis SF, Conn PJ (2001). Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J Neurosci 21:5925-5934.
34. Meltzer HY (1999). The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21:106-115.
35. Moghaddam B (2004). Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology 174:39-44.
36. Moore NA, Tye NC, Axton MS, Risius FC (1992). The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J Pharmacol Exp Ther 262:545-551.
37. O'Connor AJ, Vlachogiannis G, Moskal J, Kelso SR (1996). Subunit specific effects of D-cycloserine on NMDA receptor expressed in Xenopus oocytes. Soc Neurosci Abst 22:1530.
38. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC (1998). Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol Brain Res 56:207-217.
39. Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
40. 2 receptors in the rat striatum. Neuropsychopharmacology 25:505-513.
41. Salt TE, Binns KE (2000). Contributions of mGlu1 and mGlu5 receptors to interactions with N-methyl-D-aspartate receptor-mediated responses and nociceptive sensory responses of rat thalamic neurons. Neuroscience 100:375-380.
42. 2C antagonistic properties of newer antipsychotics. Behav Pharmacol 11:291-298.
43. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. (1996). Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124:57-73.
44. Sheinin A, Shavit S, Benveniste M (2001). Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. Neuropharmacology 41:151-158.
45. Snedecor GW, Cochran WG, editors (1980.) Statistical method. 7th ed. Ames: The Iowa State University Press.
46. Tsai G, Yang P, Chung L-C, Lange N, Coyle J (1998). D-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44:1081-1089.
47. Tsai GE, Yang P, Chung L-C, Tsai I-C, Tsai C-V, Coyle JT (1999). D-Serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry 156:1822-1825.
48. Van Berckel BN, Hijman R, Van der Linden JA, Westenberg HG, Van Ree JM, Kahn RS (1996). Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol Psychiatry 40:1298-1300.
49. Van Berckel BN, Evenblij CN, Van Loon BJAM, Maas MF, Van der Geld MAM, Wynne HJ, et al. (1999). D-Cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 21:203-210.
50. Waziri R (1988). Glycine therapy of schizophrenia. Biol Psychiatry 23:209-214.
51. Wettstein JG, Host M, Hitchcock JM (1999). Selectivity of action of typical and atypical antipsychotic drugs as antagonists of the behavioral effects of 1-2, 5-dimethoxy-4-iodophenyl-2-aminopropane (DOI). Prog Neuro-psychopharmacol Biol Psychiatry 23:533-544.
52. 2A and muscarinic receptor. Psychopharmacology 141:267-278.